Michigan Supreme Court Allows Attorney General to Probe Eli Lilly's Insulin Prices
A 4-3 split by the Michigan Supreme Court overturned a lower-court block, permitting the state attorney general to continue her investigation into Eli Lilly’s insulin pricing.
The Michigan Supreme Court voted narrowly to reverse a prior ruling that had halted the attorney general’s inquiry into Eli Lilly’s insulin costs. Attorney General Dana Nesel had launched the probe four years ago, citing state consumer-protection statutes. The investigation targets three insulin products—Lispro, Humalog and Basaglar—accused of being priced excessively high, forcing some patients to ration or seek less effective alternatives. The court’s decision reopens the case for further scrutiny.
Why it matters
The decision lets Michigan examine whether Eli Lilly’s insulin prices are unjustifiably high, affecting patient access and drug-pricing policy.
In this story